Biomarin Pharmaceutical (BMRN) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $59.1 million.
- Biomarin Pharmaceutical's Accumulated Depreciation & Amortization fell 1881.38% to $59.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year decrease of 1881.38%. This contributed to the annual value of $96.4 million for FY2024, which is 762.55% down from last year.
- Latest data reveals that Biomarin Pharmaceutical reported Accumulated Depreciation & Amortization of $59.1 million as of Q3 2025, which was down 1881.38% from $40.6 million recorded in Q2 2025.
- In the past 5 years, Biomarin Pharmaceutical's Accumulated Depreciation & Amortization ranged from a high of $108.0 million in Q4 2021 and a low of $22.1 million during Q1 2025
- For the 5-year period, Biomarin Pharmaceutical's Accumulated Depreciation & Amortization averaged around $61.3 million, with its median value being $55.2 million (2021).
- As far as peak fluctuations go, Biomarin Pharmaceutical's Accumulated Depreciation & Amortization skyrocketed by 788.2% in 2021, and later tumbled by 2449.41% in 2025.
- Quarter analysis of 5 years shows Biomarin Pharmaceutical's Accumulated Depreciation & Amortization stood at $108.0 million in 2021, then fell by 5.62% to $102.0 million in 2022, then increased by 2.37% to $104.4 million in 2023, then fell by 7.63% to $96.4 million in 2024, then plummeted by 38.69% to $59.1 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $59.1 million for Q3 2025, versus $40.6 million for Q2 2025 and $22.1 million for Q1 2025.